Biotricity, Inc.

OTCPK:BTCY Stock Report

Market Cap: US$3.6m

Biotricity Management

Management criteria checks 3/4

Biotricity's CEO is Waqaas Al-Siddiq, appointed in Jul 2014, has a tenure of 11.92 years. total yearly compensation is $1.01M, comprised of 47.6% salary and 52.4% bonuses, including company stock and options. directly owns 4.36% of the company’s shares, worth $158.17K. The average tenure of the management team and the board of directors is 5.3 years and 8.8 years respectively.

Key information

Waqaas Al-Siddiq

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage47.64%
CEO tenure11.9yrs
CEO ownership4.4%
Management average tenure5.3yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

Analysis Article • Jan 26

Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding

Biotricity, Inc. ( NASDAQ:BTCY ) shareholders that were waiting for something to happen have been dealt a blow with a...
Analysis Article • Oct 26

Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY)

When close to half the companies operating in the Healthcare Services industry in the United States have price-to-sales...
Seeking Alpha • Aug 15

Biotricity GAAP EPS of -$0.09, revenue of $2.06M

Biotricity press release (NASDAQ:BTCY): Q1 GAAP EPS of -$0.09. Revenue of $2.06M (+17.0% Y/Y).
Seeking Alpha • Jul 28

Biotricity, Inc.: A First Take

Today, we take our first look at a small medical device maker called Biotricity. Impressive growth projections lie ahead for this Busted IPO as it recently launched several important new products. An investment analysis follows in the paragraphs below. Facts do not cease to exist because they are ignored."― Aldous Huxley Today, we put Biotricity, Inc. (BTCY) in the spotlight for the first time. This medical device company finds itself in "Busted IPO" territory. However, a few new product launches should help the company deliver impressive revenue growth in the quarters and years ahead. An analysis follows below. Seeking Alpha Company Overview: This small medical device/technology solution concern is based just outside of San Francisco. The company provides biometric data monitoring solutions. Biotricity is focused on the delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The stock trades for around $1.25 a share and sports an approximate market capitalization of $70 million. The company describes itself as: Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and ​lifestyle improvement" The company's product portfolio of hardware devices and software solutions are all designed in house. Fourth Quarter Results: On July 14th, the company reported fourth quarter results. Revenues rose 80% on a year-over-year basis to $2.15 million as Biotricity posted a non-GAAP net loss of 11 cents a share. Both top and bottom line numbers were in-line with the consensus. For the full 2022 fiscal year, Biotricity had $7.7 million worth of sales, an 126% increase from FY2021. The company had a full year non-GAAP loss of 66 cents a share, 48 cents a share if you drop one-time items. The company noted on its earnings press release some notable product news during the quarter: The launch of its wireless wearable holter patch device, Biotres. This is a development leadership says represents the future of Remote Patient Monitoring. Unveiled Biokit, a personal medical device kit for integration into the Biotricity ecosystem. Launched Bioheart, a first-of-its kind continuous heart rhythm recorder and personal heart lifestyle solution. Released Biocare Cardiac, a personal, cardiac health application for individuals diagnosed with, or at risk for, cardiovascular disease. Leadership seems particularly excited by two of these launches. Bioheart, its cardiac monitor now directly available to consumers offers the same continuous heart monitoring technology used by physicians. The patient can now manage heart conditions with retrospective snapshots and long-term data collection in a state-of-the-art manner. The device is worn directly around the chest and goes for just under $200 on Amazon. Bioheart measures your heart's electrical activity with high accuracy. The device is small and lightweight, and at approximately 2.5 inches in diameter can fit in the palm of your hand. It can be set up in a few minutes, starting by downloading the Bioheart app. This device can improve remote patient monitoring significantly and is very relevant to senior citizens as doctors can use this data to diagnose and treat heart rhythm irregularities with minimal in-person visits. In this way it advances Telehealth. The company believes this adds an approximate $1.25 billion annual market to its target population.
Analysis Article • Apr 09

Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Dec 11

Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 31

Biotricity: Capital Raise Leads To Buying Opportunity

BTCY recently announced a capital raise, leading to a sudden and significant decrease in the share price. With likely catalysts ahead, and continued stellar growth in its core business, the recent share price drop presents a compelling buying opportunity. In conjunction with the secondary offering, BTCY has now been uplisted to Nasdaq, providing more visibility and liquidity in the stock. Anapp currently under development by BTCY could blow the top off all current management guidance and analyst estimates. While there are certainly risks, the stock could conceivably double over the next year.

CEO Compensation Analysis

How has Waqaas Al-Siddiq's remuneration changed compared to Biotricity's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$5m

Sep 30 2025n/an/a

-US$5m

Jun 30 2025n/an/a

-US$6m

Mar 31 2025US$1mUS$480k

-US$12m

Dec 31 2024n/an/a

-US$14m

Sep 30 2024n/an/a

-US$16m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024US$1mUS$480k

-US$15m

Dec 31 2023n/an/a

-US$15m

Sep 30 2023n/an/a

-US$17m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023US$1mUS$480k

-US$20m

Dec 31 2022n/an/a

-US$21m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$29m

Mar 31 2022US$887kUS$480k

-US$30m

Dec 31 2021n/an/a

-US$30m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$19m

Mar 31 2021US$891kUS$390k

-US$16m

Dec 31 2020n/an/a

-US$16m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020US$2mUS$390k

-US$11m

Compensation vs Market: Waqaas's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD647.34K).

Compensation vs Earnings: Waqaas's compensation has been consistent with company performance over the past year.

CEO

Waqaas Al-Siddiq (41 yo)

11.9yrs
Tenure
US$1,007,596
Compensation

Dr. Waqaas Al-Siddiq, PhD, has founded Biotricity Inc. (formerly known as iMedical Innovations Inc.) in July 2014 and has been its Chairman, President and Chief Executive Officer since July 2014. Dr. Al-Si...

Leadership Team

NamePositionTenureCompensationOwnership
Waqaas Al-Siddiq
Founder11.9yrsUS$1.01m4.36%
$ 158.2k
S. Ayanoglou
Chief Financial Officer8.7yrsUS$738.02k2.56%
$ 92.9k
Amjad Talpur
Senior Director of Operationsno datano datano data
Matt Zabel
Vice President of Sales & Strategyno datano datano data
Amir Ali
Chief Development Officerno datano datano data
Spencer LaDow
CISO and Executive VP of Engineering & Regulatoryless than a yearno datano data
Fareeha Siddiqui
Executive Vice President of Healthcare Solutions2yrsno datano data
5.3yrs
Average Tenure

Experienced Management: BTCY's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Waqaas Al-Siddiq
Founder11.9yrsUS$1.01m4.36%
$ 158.2k
John Simpson
Chair of Scientific & Medical Alliance Board and Chair of Science Alliance Board6.3yrsno datano data
Daniel Sands
Member of the Board of Advisors10.1yrsno datano data
Ronald McClurg
Independent Director4.1yrsUS$24.80k0.11%
$ 4.0k
David Rosa
Independent Director10.1yrsUS$104.01k0.81%
$ 29.3k
J. Rice
Member of the Board of Advisors10yrsno datano data
John Rother
Member of the Board of Advisors10.1yrsno datano data
Thomas Nelson
Member of the Board of Advisors10yrsno datano data
Donald Cross
Member of Scientific & Medical Alliance Board7.6yrsno datano data
Edward Lazaga
Member of Scientific & Medical Alliance Board7.6yrsno datano data
Imran Mohiuddin
Member of Scientific & Medical Alliance Board7.6yrsno datano data
Radoslaw Kiesz
Member of Scientific & Medical Alliance Board7.6yrsno datano data
8.8yrs
Average Tenure
66yo
Average Age

Experienced Board: BTCY's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 01:38
End of Day Share Price 2026/06/29 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biotricity, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kevin DedeH.C. Wainwright & Co.
Jason WittesNorthland Capital Markets